Aldesleukin
- Generic Name
- Aldesleukin
- Brand Names
- Proleukin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 110942-02-4
- Unique Ingredient Identifier
- M89N0Q7EQR
- Background
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
- Indication
For treatment of adults with metastatic renal cell carcinoma.
- Associated Conditions
- Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)
- Associated Therapies
- -
Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 72
- Registration Number
- NCT00000948
- Locations
- 🇹🇭
Siriraj Hospital C603-020 CRS, Bangkok, Ratchathewi, Thailand
🇹🇭Chulalongkorn Univ. Hosp. C603-010 CRS, Bangkok, Ratchathewi, Thailand
A Study to Test the Safety of Recombinant Interleukin-2 (rIL-2) in HIV-Infected Children
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 27
- Registration Number
- NCT00000849
- Locations
- 🇺🇸
Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States
🇺🇸Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California, United States
🇺🇸Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States
The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 72
- Registration Number
- NCT00000825
- Locations
- 🇺🇸
Thomas Street Clinic C605-020 CRS, Houston, Texas, United States
Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2016-12-14
- Target Recruit Count
- 16
- Registration Number
- NCT00000875
- Locations
- 🇺🇸
The Ctr For Blood Research Inc, Boston, Massachusetts, United States
Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 20
- Registration Number
- NCT00000728
- Locations
- 🇺🇸
Stanford Univ School of Medicine, Stanford, California, United States
Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 92
- Registration Number
- NCT00006066
- Locations
- 🇺🇸
Nyu Ny Nichd Crs, New York, New York, United States
🇺🇸Children's National Med. Ctr. Washington DC NICHD CRS, Washington, District of Columbia, United States
🇺🇸Usc La Nichd Crs, Los Angeles, California, United States
Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection
- Conditions
- HIV InfectionsHepatitis C
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 24
- Registration Number
- NCT00015652
- Locations
- 🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
🇺🇸UCLA CARE Center CRS, Los Angeles, California, United States
A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-05-21
- Target Recruit Count
- 200
- Registration Number
- NCT00000870
- Locations
- 🇺🇸
The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States
🇺🇸Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States
🇺🇸Case CRS, Cleveland, Ohio, United States
Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-11-02
- Target Recruit Count
- 92
- Registration Number
- NCT00013663
- Locations
- 🇺🇸
New York Hosp - Cornell Med Ctr, New York, New York, United States
Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 78
- Registration Number
- NCT00000821
- Locations
- 🇺🇸
Natl Inst of Allergy & Infect Dis / Cln Ctr, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.